GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Beijing Science Sun Pharmaceutical Co 300485.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

7.72

-1.40%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Beijing Science Sun Pharmaceutical Co

Its shares trade on Shenzhen under the ticker 300485.SZ. It has been listed since 26 June 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥404.7m and net income of CN¥14.6m. At that date it held total assets of CN¥3.57bn and shareholders' equity of CN¥3.37bn.

Beijing Science Sun Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of bio-pharmaceutical products. The company is headquartered in Beijing, Beijing. The company went IPO on 2015-06-26. The Company' products can be divided into cardiovascular series, immune regulation series, nervous system series and other natural or biotech pharmaceuticals. Its products include small capacity injection and freeze-dried powder injection.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
26 Jun 2015
Employees
559
Website
ssyy.com.cn ↗

Leadership

Pay as last reported

  • Mr. Biao MaChairman of the Board, General Manager, since 2001CN¥540,600
  • Ms. Dongna LiangChief Financial Officer
  • Mr. Yinfu ShenChief Marketing OfficerCN¥326,400
  • Mr. Xuefeng WangDeputy General Manager, Secretary of the Board, Director, since 2006CN¥449,100
  • Ms. Li MaDeputy General Manager, Director, since 2006CN¥508,200
  • Mr. Shuangquan KongChief EngineerCN¥533,800
  • Mr. Wentao XuDirectorCN¥60,000
  • Mr. Changcheng YinDirectorCN¥60,000
  • Mr. Yunping DaiIndependent Director
  • Mr. Feng LiuIndependent Director
  • Ms. Yanheng SongIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Beijing Science Sun Pharmaceutical employs 559 skilled employees in biotechnology sector.
  • Cardiovascular series products are a key strength in their pharmaceutical portfolio.
  • Natural and biotech pharmaceuticals include small capacity injection and freeze-dried powder injection.

Weaknesses

  • Limited product range compared to global biotech competitors.
  • Dependence on cardiovascular series for significant revenue generation.
  • No mention of international market presence in current business description.

Opportunities

  • Expanding into immune regulation series for potential market growth.
  • Increasing demand for nervous system series pharmaceuticals in China.
  • Growing biotech sector in Beijing offers collaborative opportunities.

Threats

  • Intense competition within the Chinese biotechnology industry.
  • Regulatory changes could impact production of biotech pharmaceuticals.
  • Economic downturns may reduce healthcare spending in China.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.